Who we are

A team you can rely on

Since our inception in 2006, not only have we established and nurtured an experienced and dedicated  workforce, we have also built what we believe to be a best-in-class executive team.

Our client-focused and flat structure of our organisation mean that our leadership team remain easily accessible to all project sponsors, irrespective of size or value. Our senior management is always on hand to support operational teams to deliver a swift resolution to any issues that might arise.

Management board

Chief Executive Officer

Andrew Copestake

Andrew has almost 30 years industry experience, having worked in large multinational pharmaceutical companies, global and regional contract research organizations, the biotech sector, as well as other service providers. He brings a global approach, having gained international experience during appointments in the USA, Japan and throughout Europe.

Andrew joined Optimapharm’s executive management team in July 2020 following several months advising the company’s Board of Directors.

Andrew holds a PhD in Respiratory & Exercise Physiology from Loughborough University, UK and a Bachelor Degree (Hons) in Applied Biology from East London University, UK. He is also a Fellow of the Royal Society of Medicine.

Chief Operating Officer

Gordana Gregurić Čičak

Gordana has held the position of Chief Operating Officer at OPTIMAPHARM since July 2020, and is responsible for leading the Company’s operations and for securing high functionality and performance of Clinical Operations, Clinical Project Management and Regulatory & Safety Departments.

Gordana founded OPTIMAPHARM in 2006 and performed the CEO function for 14 years, growing the company from SEE regional niche player to mid-sized, full-service European CRO.

Prior to that, Gordana excelled in both Clinical Project Management and Senior Management positions within leading global (Ingenix, i3 research) and international CRO companies (Ergomed, SAR Monitoring Services), including regional and country business responsibilities. She was also a Board Member at the Ingenix Pharmaceutical Services (i3 research) in Croatia.

Gordana graduated from the School of Medicine at the University of Zagreb in 1995. In 2001, she completed postgraduate studies in Clinical Pharmacology and Toxicology.

Chief Financial Officer

Walter Miller

Walter has over 25 years industry experience, with demonstrated capabilities in fast growing companies, having worked in several international biotech companies and European CRO. As CFO he was responsible for Corporate Finance, Legal, IT, HR as well as the Risk Management, Compliance and Corporate Governance. Prior to that, Walter hold several senior manager positions in Finance and Operations. He has led and worked on various international projects related to financing/IPO, financial due diligence, valuation projects as well as M&A and in- and out-licensing activities.

From December 2020 onwards Walter took over responsibility as Chief Financial Officer at Optimapharm.

Walter holds a Master of Science in Economics from University of Applied Sciences in Aachen, Germany, a Bachelor of Arts in Studies of Sciences on Marriage and Family from MEDO International Academic Institute for Studies on Marriage and Family, Kerkrade, Netherlands and holds a controller‘s-diploma from the Controller Akademie in Gauting, Germany.

Stanislav Bachvarov

Mr. Bachvarov focuses on supporting the Team’s efforts across sourcing, evaluating, executing and monitoring investments.

Prior to joining TRG, he was a Visiting MBA Associate at Duke Street Capital and One Equity Partners in 2016 where he worked on private equity investments in the Healthcare and TMT sectors. From 2014 to 2015 he was seconded as an Analyst at the Goldman Sachs Merchant Banking team focusing on analyzing private debt principal investments across all industries. From 2011 to 2014, Mr. Bachvarov was a strategy consultant with Accenture and Deloitte advising clients on operational and strategic improvement initiatives.

Mr. Bachvarov earned an MBA with Distinction from London Business School. He also holds a Bachelor of Arts (Honours) degree in Business and Economics from the American University in Bulgaria and a Master of Science degree in Statistics from Warwick Business School. Mr. Bachvarov is fluent in Bulgarian and Russian.

Leadership team

Vice-President, Clinical Operations

Ana Stojković

Ana holds Doctor of Dental Medicine degree from the School of Dentistry, University of Zagreb, Croatia. In 2006, she also completed postgraduate studies and defended her Master Thesis in Infectology.

After 7 years of working in clinical dentistry field with adults and children, Ana joined the Medical Department at GlaxoSmithKline.

During the 6 years in GSK Ana first assumed CRA role and subsequently Clinical Research Scientist role. During that time, besides clinical operations activities Ana was also involved in the Regulatory department activities, Medical advising and Vendor management.

In 2008, Ana joined OPTIMAPHARM and during long term career in the company she contributed in different clinical roles. Ana has also gained invaluable experience in the preparation and hosting of FDA inspections. In 2012, Ana established the company yearly advanced training program OPTIMAPHARM GCP Academy. From 2021 Ana is preforming function of VP Clinical Operations.

Furthermore, Ana is EAIP certified Integrative Psychotherapist.

Vice-President, Clinical Project Management

Anamaria Džoja Horvat

Anamaria graduated from the School of Pharmacy and Biochemistry, University of Zagreb. She has over 16 years of international clinical research experience in the fields of Clinical Operations and Clinical Project Management covering various therapeutic areas but with special expertise in oncology, CNS and metabolic diseases.

In 2008, Anamaria joined OPTIMAPHARM’s team, obtaining different roles in the company: sCRA, Clinical Project Manager, Country Manager and Clinical Project Management Director.

In 2020, she assumed the role of Vice President Clinical Project Management and is responsible for the management, strategic planning, development and execution of all Clinical Project Management activities.

Anamaria is actively involved in the development of various company training programs, company quality activities and internal organizational management projects.

Vice-President, Data Management and Biostatistics

Juan Vicente Torres

Juan Vincente has experience in various spheres of research such as the public sector, contract research organizations, and pharmaceutical companies. He successfully ran his own company Syntax for Science as CEO until its merger with Optimapharm in December 2020.

Juan Vincente joined OPTIMAPHARM’s team as Vice President Data Management and Biostatistics and is responsible for the overall management, strategic planning, development and execution of Data Management and Biostatistics activities in the Company.

He holds a master’s degree in Biostatistics (UPC). A bright professional with over 15 years of experience in clinical research. His specialty is in combining a vigorous knowledge of theoretical statistics with advanced skills in SAS® programming.

Juan Vicente has an innate and highly developed sense of entrepreneurship mainly focused on collaboration and continuous improvement. He is founder member of the Catalonian Statistical Society, member of the International Biometric Society, and recently he has been elected as new president of the Biotecnological and Biomedical Cluster of the Balearic Islands.

Medical Affairs Director

César García-Rey

César holds a Medical Degree from the Universidad Complutense de Madrid and also a specialization in Clinical Microbiology and Infectious Diseases from the Hospital General Universitario Gregorio Marañón, Madrid.

César has more than 20 years of experience in Clinical Research and has worked for different Pharmaceutical companies in different therapeutic areas. He has also participated in numerous clinical studies and is author of over 60 papers with more than 2,300 citations.

In 2020, César joined Optimapharm’s team as Medical Affairs Director, responsible for execution and coordination of medical affairs activities, including providing strong leadership, guidance, and insight to oversee the successful execution and implementation of Optimapharm’s medical affairs strategy.

Senior Director Business Development

Marie-Dominique Garchon

Marie Dominique brings 25 years of Business Development experiences in the global pharmaceutical market.

Before joining Optimapharm, Marie Dominique sold CRM solutions for Sales Reps and spent more than 10 years in developing Continuous Medical Education through the promotion of European Medical Conferences. She then moved to the CRO industry 12 years ago and build her expertise in LabCorp and more recently at Syneos Health, developing Businesses across Europe. As a proven team leader with a passion for providing high quality service, Marie Dominique always promotes continuous improvement initiatives within the organizations.

Marie Dominique holds a Specialized Master in International Business Engineering from EDHEC Lille. She is fluent in French, English, and Spanish.

Senior Quality Assurance and Training Director

Margaret McKee

Margaret is a Quality Assurance expert with over 20 years’ experience in senior Quality Assurance and operational roles across global CROs and Biotech and all phases of clinical research.

Margaret holds a record of the successful implementation and leadership of GxP quality management systems, global QA and training functions and quality risk management. She managed client audits and regulatory inspections globally including FDA, EMA, MHRA, HPRA, PMDA (Japan), ANMAT (Argentina), ANVISA (Brazil), KFDA (Korea), and DCGI (India) inspections.

Margaret has also led various process improvement, operational change, IT system implementation and integration initiatives.

Margaret has comprehensive global GxP, regulatory and business leadership knowledge and has led and participated in many internal business, client, and contractor partnership relationships.

Margaret qualified as an analytical chemist followed by post graduate management and leadership qualifications and is a longstanding member of RQA (Research Quality Association).

Regulatory Affairs Director

Vladimir Vujović

Vladimir holds a Master of Pharmacy degree from the School of Pharmacy, University of Belgrade. Before joining Optimapharm in January 2016, he worked at large pharma companies within regional regulatory affairs groups, where he was responsible for marketing authorization submissions and management of post-authorization lifecycle activities. He also managed regional regulatory activities for cardiovascular implantable and in-vitro diagnostic portfolio for a large global medical device company.

Since early 2020, he was appointed to the position of Regulatory Affairs Director, and is currently responsible for the departmental delivery, primarily in the aspects of management of clinical trial applications and site contract negotiation, providing strategic regulatory input and development of company regulatory infrastructure. He is an active member of several professional organizations, such as DIA, RAPS and TOPRA, as well as the medical device group of the local Standards Body (ISO member).

Supervisory board

Harold Chatelus

Mr. Chatelus focuses on sourcing, evaluating, executing and monitoring investments across Europe. He currently serves on the Board of Directors of two portfolio companies, Pet Network International (Croatia) and Optimapharm (Croatia).

Prior to joining TRG in December 2013, he was a member of the Citi Venture Capital International (CVCI) investment team from 2011. At CVCI, Mr. Chatelus focused on investments in the pharmaceutical and retail sectors and served on the Board of Directors of three portfolio companies. From 2008 to 2011, Mr. Chatelus was an Associate in Citi’s London-based Emerging Markets M&A team, advising clients across all industries on M&A transactions throughout the CEEMEA region. From 2006 to 2008, he was an Analyst in Citi’s Global Financial Institutions investment banking team, based in New York, where he advised clients on M&A transactions and debt and equity financing.

Mr. Chatelus earned a Bachelor of Science in Foreign Service (International Economics) from Georgetown University’s School of Foreign Service. He is fluent in French, Italian and Spanish.

Colin Clark

Mr. Clark heads The Rohatyn Group’s (“TRG”) private equity business in EMEA. He focuses on investing in high quality companies with superior growth potential across Europe in the Consumer, Healthcare and TMT sectors. He currently serves on the Board of Directors of five portfolio companies in Europe: Pet Network International (Pet Supplies), Amethyst Radiotherapy (Specialised Radiotherapy Treatment Centres), Optimapharm (European CRO), Tallink (Ferry & Short Cruise Operator) and Prestige (Branded Biscuits & Wafers). He has held numerous board positions over the past 18 years in both public and private companies and sits on various investment committees within TRG.

Prior to joining TRG in December 2013, Mr. Clark was a Partner at Citi Venture Capital International (“CVCI”) and a member of the investment team from 2003. During this period, he led and successfully exited multiple investments across Europe for CVCI. Before CVCI, Mr. Clark originated and structured project finance transactions for Citi across the EMEA region. From 1996 to 2000, he worked with Bank of Scotland in Edinburgh in various positions in project finance and acquisition finance.

Mr. Clark has a bachelor’s degree in Accountancy and Management from the University of Dundee, Scotland and is a member of the Institute of Chartered Accountants of Scotland.

Charles Woler

Dr Charles Woler has over 35 years’ experience in the pharmaceutical, biotech and medtech industry in Europe and the United States.

He was formerly Chairman and CEO of Roche France, Smith Kline Beacham President of Europe Pharmaceuticals in London, President and CEO of Cadus Pharmaceutical (US), before becoming CEO of venture capital backed biotechs Neuro3d and Endotis Pharma. As Executive GM at the Biomnis Group, Charles led the negotiations when the company was sold to Eurofins Scientific.

More recently Charles has built a portfolio of non-executive assignments across different areas of the life sciences sector, in different countries, and played a pivotal role in the successful execution of exit strategies for several of these, including as Chair, the acquisition of full site CRO Synexus by PPD, the sale of Citoxlab to Charles River, and recently the sale of ERBC, a preclinical CRO to the private equity fund UI Investissement.

Igor Čičak

Igor is founder of Optimapharm and from 2011 until 2020 he was Chairman of the Supervisory Board. During that period, Optimapharm realized impressive growth of business, from the position of reginal niche player to a leading full service mid-size European CRO. After TRG investment in Optimapharm in early 2020, Igor maintained significant minority equity stake in the company and SB position.

Igor is also CEO and the Founder of an investment firm Provectus Capital Partners (PCP). PCP has created Adriatic Structured Equity Fund (ASEF), a Luxemburg based PE fund which is providing equity investments in established mid-market businesses in SEE, with the focus on private health care sector.

Igor graduated at Faculty of Economics and Business in Zagreb, has completed GMP program in Vienna and Senior Executive Program at London Business School.

“It has been great working with Optimapharm during 2021, you have exceeded the expectations. Thank you for all you have done and are doing for us. I look forward to even better collaboration during 2022.”

Country Head

Let’s talk about your pharma study needs